HOME >> BIOLOGY >> NEWS
Results from open-label Raptiva study suggest continued benefit with long-term treatment

Genentech, Inc. and XOMA Ltd. today announced preliminary results from an open-label, multicenter trial evaluating the long-term safety and tolerability of continuous RaptivaTM (efalizumab) treatment in patients with moderate-to-severe psoriasis.

"The findings from this important open-label study on the long-term safety and efficacy of Raptiva are very encouraging and further support Raptiva's potential to address the unmet medical need of patients with moderate-to-severe psoriasis," said Hal Barron M.D., FACC, Genentech's vice president, Medical Affairs.

Alice Gottlieb, M.D., director of the Clinical Research Center at the Robert Wood Johnson Medical School at the University of Medicine and Dentistry of New Jersey presented data for patients receiving continuous Raptiva treatment for one year following an initial three months of treatment. The data were presented on Saturday, March 22 at the 61st annual American Academy of Dermatology meeting being held in San Francisco.

Response Rates with Continued Raptiva Treatment

A total of 339 patients were enrolled in this continuing open-label, multicenter study. 41 percent of patients (140/339) achieved 75 percent or greater improvement in Psoriasis Area and Severity Index (PASI) scores (PASI 75) and 82 percent (278/339) achieved PASI 50 or greater improvement after 12 weeks of 2 mg/kg/week Raptiva therapy. Patients who achieved a PASI 50 score or OLS (Overall Lesion Severity scale) of clear, minimal or mild at week 12 were eligible to enter the continuous treatment period. Of the original 339 patients, 290 patients who met the entry criteria for the maintenance period entered the continuous treatment phase of the study. For each successive three-month period of treatment, dropouts during that cohort period were counted as non-responders for that cohort, but were excluded from the subsequent cohorts.

Starting from week 13, the wee
'"/>

Contact: Emmy Tsui
emmy.tsui@ketchum.com
646-935-4019
Ketchum
24-Mar-2003


Page: 1 2 3 4 5

Related biology news :

1. Results of pivotal study for GlaxoSmithKlines Valtrex published in New England Journal of Medicine
2. NASA Materials Conference Features Science Results, Experts on Technologies for Exploration
3. Abgenix Reports Encouraging Preclinical Results With ABX-EGF In Cancer Research
4. Encouraging Results In Preclinical Studies Of Parkinsons Disease Gene Therapy
5. Quicker Implementation Of Research Results
6. Results Of Poisoning Visible In Urine
7. Phase III Results Suggest Potent Antiviral Activity For Vertex And Glaxo Wellcomes Second-Generation HIV Protease Inhibitor Agenerase TM
8. New Gene Therapy Technique Results In Efficient Gene Delivery
9. False Security: You Cant Always Believe The Results Of A Genetic Test
10. Cell Pathways Reports Extension Study Results Showing Ability Of FGN-1 To Prevent Formation Of Precancerous Colon Polyps
11. Results Of Hog-Stress Study May Lead To Better Management Methods

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/29/2018)... ... August 28, 2018 , ... Johanna Dwyer, founder and Chief ... of excellence in the field of intellectual property, and named Daniela Sanchez as ... IP Award aims to encourage and support women in their pursuit of careers ...
(Date:8/26/2018)... ... August 23, 2018 , ... Clinical ... sensitivity and specificity over more commonly used analytical techniques. However, implementation can be ... of development and validation of methods that must be undertaken by the laboratory ...
(Date:8/23/2018)... ... August 21, 2018 , ... Mandy is an eight-year-old mini Australian shepherd and a tripod. ... She went through three surgeries to try to repair the leg and each time ... the leg so her owner, along with her veterinarian, decided to amputate. With only ...
Breaking Biology News(10 mins):
(Date:8/29/2018)... ... August 28, 2018 , ... CEO ... of a safety study performed on an allogeneic (donor derived) stem cell product ... Association (NAVRMA) conference in September. He is also the organizer of Breakout ...
(Date:8/23/2018)... ... August 22, 2018 , ... Crucial Data Solutions, Inc. ... it the first fully-featured app for electronic data capture (EDC) and electronic participant ... constitute 99 percent of the market share for mobile devices worldwide; in turn, ...
(Date:8/17/2018)... ... August 16, 2018 , ... KCAS Bioanalytical and Biomarker Services, ... of their team. Dr. Dawn Dufield, Ph.D., joins KCAS as Director of BioPharma. ... group that will specialize in developing quantitative LC-MS/MS assays for biopharma molecules. Dr. ...
(Date:8/14/2018)... ... 14, 2018 , ... The growing interest in PEEK-OPTIMA™ spinal ... Association of Orthopaedic Surgeons (CAOS) held in partnership with the North American Spine ... and Invibio Biomaterial Solutions partnered to demonstrate the new Uplifter® Expandable ...
Breaking Biology Technology:
Cached News: